Cite
HARVARD Citation
Gilligan, A. et al. (2019). Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin. Expert review of pharmacoeconomics & outcomes research. pp. 203-212. [Online].